How long can a patient with lung cancer brain metastasis live in coma

How long can a patient with lung cancer brain metastasis live in coma? This is a question that many advanced patients and their families are concerned about. They often ask their attending physicians questions like how long a patient with brain metastasis can live. For questions like how long a patient with brain metastasis can live, it is difficult to get a clear answer.

In other words, the survival time of patients with advanced lung cancer mainly depends on the correct treatment method and the patient's physical function. In addition, patients with advanced lung cancer and their families should understand the treatment of advanced lung cancer and communicate with the attending physician, which will help prolong the survival of advanced lung cancer. The main factors affecting the survival of brain metastases from lung cancer are the treatment method and the patient's physical condition.

Whether the treatment of lung cancer is appropriate is the most important factor affecting the survival of brain metastases from lung cancer. As far as the treatment of advanced lung cancer is concerned, the possibility of surgical resection is very low. In clinical practice, the main treatments for advanced lung cancer are radiotherapy, chemotherapy and traditional Chinese medicine.

35% of patients with advanced lung cancer can relieve symptoms after radiotherapy. External irradiation of different doses and fractions can relieve local symptoms of primary or metastatic lesions. However, due to the damage of radiotherapy to normal cells, the physical function of patients with advanced lung cancer is very weak, and radiotherapy should be used with caution. In addition, platinum is the most commonly used chemotherapy regimen for patients with advanced lung cancer. In addition, drugs such as taxane, norvinblastine, and gemcitabine are also widely used in the treatment of advanced lung cancer.

However, as the duration of chemotherapy increases, its treatment toxicity gradually increases. Therefore, the selection and timing of chemotherapy drugs should be based on tumor remission, symptom relief, and treatment-related toxicity. In view of the toxicity and side effects of radiotherapy and chemotherapy on the human body, the treatment of advanced lung cancer can be combined with traditional Chinese medicine to play a synergistic detoxification effect. For patients with advanced lung cancer with extensive metastasis, weak physical function, and intolerance to chemotherapy, Chinese medicine can be used for radical cure. Although the short-term effect is not obvious, the long-term effect is good, and the effect of improving the quality of life and prolonging survival time is obvious.

In addition, the improvement of the patient's physical function is also an important factor in determining the survival time of brain metastasis of lung cancer. Good physical function and strong immunity can resist the development of cancer and tolerance to various drugs. Therefore, it is very important to improve the immune function and anti-tumor ability of patients with advanced lung cancer.

How long can a patient with lung cancer brain metastasis live? In other words, how long can a patient with advanced lung cancer live? This depends mainly on whether the treatment method is appropriate and the patient's physical function. In addition, patients with advanced lung cancer and their families should learn more about the treatment of advanced lung cancer and communicate more with their attending physicians, which will help prolong the survival of advanced lung cancer. The main factors affecting how long a patient with lung cancer brain metastasis can live are the treatment method and the patient's physical condition.

Whether the treatment of lung cancer is appropriate is the most important factor affecting how long a person with lung cancer brain metastasis can live. As for the treatment of advanced lung cancer, the possibility of surgical resection is very low. The main treatments for advanced lung cancer in clinical practice include radiotherapy, chemotherapy, and traditional Chinese medicine.

Thirty-five percent of patients with advanced lung cancer experience relief of symptoms after radiotherapy. External radiotherapy with different doses and fractions can relieve local symptoms of primary or metastatic lesions. However, since radiotherapy can also cause damage to normal cells, radiotherapy should be used with caution for patients with advanced lung cancer who have very weak physical functions. In addition, the most commonly used chemotherapy regimen for patients with advanced lung cancer is the platinum regimen. In addition, taxanes, norvinblastine, gemcitabine and other drugs are also widely used in the treatment of advanced lung cancer. However, as the duration of chemotherapy increases, its treatment toxicity is also gradually increasing. Therefore, the choice of chemotherapy drugs and chemotherapy time should be based on the tumor relief, symptom relief and treatment-related toxicity. In view of the toxic and side effects of radiotherapy and chemotherapy on the human body, traditional Chinese medicine can be combined with treatment in the treatment of advanced lung cancer to enhance efficacy and reduce toxicity. For patients with advanced lung cancer with a wide range of metastases, weak physical functions, and difficulty in tolerating chemotherapy, radical treatment with traditional Chinese medicine can be used. Although the short-term effect is not as obvious as chemotherapy, the long-term effect is good, and the effect of improving the quality of life and prolonging survival is obvious.

In addition, the improvement of the patient's physical function is also an important factor in determining how long a patient with lung cancer brain metastasis can live. Only with good physical function and strong immunity can one resist the development of cancer and tolerate various drug treatments. Therefore, improving immune function and enhancing resistance to tumors is extremely important for patients with advanced lung cancer.